nach oben

Die Kardiologie

Erschienen in:

01.08.2010 | Diagnostische Elektrophysiologie und Devices

Stellenwert von Belastungsuntersuchungen bei nichtischämischen Herzerkrankungen

verfasst von: PD Dr. G. Plehn, T. Butz, A. Meissner, H. Yeni, M. Prull, J. Vormbrock, H.J. Trappe

Erschienen in: Die Kardiologie | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

Traditionell haben Belastungsuntersuchungen einen hohen Stellenwert in der Diagnostik kardiovaskulärer Erkrankungen. Darüber hinaus spielt das Belastungsprinzip eine wachsende Rolle in der klinischen und wissenschaftlichen Aufarbeitung von Patienten mit valvulären und myokardialen Herzerkrankungen. Die Mehrzahl herzinsuffizienter Patienten ist unter Ruhebedingungen beschwerdefrei und entwickelt erst unter körperlicher Belastung Symptome. Ursache ist eine Verminderung der kardialen Pumpreserve. Geringe Störungen der Herzfunktion sind unter Ruhebedingungen oft inapparent, da ihre hämodynamischen Effekte klinisch nicht fassbar sind und die kardiale Förderleistung normal ist. Die Mehrbeanspruchung unter körperlicher Belastung führt dagegen zu einer Exazerbation dieser Störungen und ihrer nachteiligen Folgen für die zentrale Hämodynamik. Entsprechend können Belastungsuntersuchungen ein wichtiges diagnostisches Instrument sein, um den Brückenschlag zwischen körperlichen Symptomen und einer zugrunde liegenden Funktionsstörung des Herzens herzustellen und damit eine kardiale Diagnose zu sichern.

Lieberman DE, Bramble DM (2007) The evolution of marathon running: capabilities in humans. Sports Med 37:288–290CrossRefPubMed

Zimmer C (2004) Human evolution. Faster than a hyena? Running may make humans special. Science 306:1283CrossRefPubMed

Bramble DM, Lieberman DE (2004) Endurance running and the evolution of Homo. Nature 432:345–352CrossRefPubMed

Higginbotham MB (1988) Cardiac performance during submaximal and maximal exercise in healthy persons. Heart Failure 4:68–76

Ekblom B, Hermansen L (1968) Cardiac output in athletes. J Appl Physiol 25:619–625PubMed

Swedberg K, Gundersen T (1993) The role of exercise testing in heart failure. J Cardiovasc Pharmacol 22(Suppl 9):13–17

Rost R (1990) Herz und Sport: eine Standortbestimmung der modernen Sportkardiologie, Beiträge zur Sportmedizin: Bd. 22. Perimed Fachbuch Verlags-Gesellschaft, Erlangen

Tan YT, Wenzelburger F, Lee E et al (2009) The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol 53:36–46CrossRef

Grosu A, Bombardini T, Senni M et al (2005) End-systolic pressure/volume relationship during dobutamine stress echo: a prognostically useful non-invasive index of left ventricular contractility. Eur Heart J 26:2404–2412CrossRefPubMed

10.

Levine RA (2004) Dynamic mitral regurgitation – more than meets the eye. N Engl J Med 351:1681–1684CrossRefPubMed

11.

Osler W (1895) The principles and practice of medicine. Young J Pentland, Edinburgh, S 671

12.

Burgess MI, Jenkins C, Sharman JE et al (2006) Diastolic stress echocardiography: hemodynamic validation and clinical significance of estimation of ventricular filling pressure with exercise. J Am Coll Cardiol 47:1891–1900CrossRefPubMed

13.

Gerdts E, Bjornstad H, Toft S et al (2002) Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). J Hypertens 20:1223–1229CrossRefPubMed

14.

Plehn G, Vormbrock J, Christ M et al (2009) Provocation of masked diastolic dysfunction by exercise testing in hypertensive heart failure patients with normal ejection fraction and normal or mildly increased LV mass. Acta Cardiol 64:617–626CrossRefPubMed

15.

Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10:165–193CrossRefPubMed

16.

Maron MS, Olivotto I, Zenovich AG et al (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114:2232–2239CrossRefPubMed

17.

Bonow RO, Carabello BA, Chatterjee K et al (2008) 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118:e523–e661CrossRefPubMed

18.

Zhou Q, Henein M, Coats A et al (2000) Different effects of abnormal activation and myocardial disease on left ventricular ejection and filling times. Heart 84:272–276CrossRefPubMed

19.

Plehn G, Vormbrock J, Machnick S et al (2009) Disproportionate shortening of diastolic time and cardiac performance in asymptomatic patients with aortic regurgitation. J Heart Valve Dis 18:9–17PubMed

20.

Franciosa J, Park M, Levine TB (1981) Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol 47:33–39CrossRefPubMed

21.

Plehn G, Vormbrock J, Lefringhausen L et al (2009) Prevalence of ventricular discordance and its relation to functional capacity in idiopathic dilated cardiomyopathy. Clin Res Cardiol 98:371–378CrossRefPubMed

22.

Metra M, Raddino R, Dei Cas (1990) Assessment of peak oxygen consumption, lactate and ventilatory threshold and correlation with resting and exercise haemodynamic data in chronic congestive cardiac failure. Am J Cardiol 65:1127–1133CrossRefPubMed

23.

Jäger D, Baberg HT, Machraoui A et al (1999) Problematik der klinischen Einschätzung der Ruhe- und Belastungshämodynamik bei chronisch Herzkranken. Med Klin 94:659–664CrossRef

24.

Wilson JR, Rayos G, Yeoh TK et al (1995) Dissociation between exertional symptoms and circulatory function in patients with heart failure. Circulation 92:47–53PubMed

25.

Raphael C, Briscoe C, Davies J et al (2007) Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart 93:476–482CrossRefPubMed

26.

European Society of Cardiology, Heart Failure Association of the ESC (HFA), European Society of Intensive Care Medicine (ESICM) et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10:933–989CrossRef

27.

Opasich C, Pinna GD, Mazza A et al (1998) Reproducibility of the six-minute walking test in patients with chronic congestive heart failure: practical implications. Am J Cardiol 81:1497–1500CrossRefPubMed

28.

O’Neill JO, Young JB, Pothier CE et al (2005) Peak oxygen consumption as a predictor of death in patients with heart failure receiving {beta}-blockers. Circulation 111:2313–2318CrossRef

29.

Metra M, Faggiano P, D’Aloia A et al (1999) Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. J Am Coll Cardiol 33:943–950CrossRefPubMed

30.

Williams SG, Cooke GA, Wright DJ et al (2001) Peak exercise cardiac power output; a direct indicator of cardiac function strongly predictive of prognosis in chronic heart failure. Eur Heart J 22:1496–1503CrossRefPubMed

31.

Myers J, Gujja P, Neelagaru S et al (2007) Cardiac output and cardiopulmonary responses to exercise in heart failure: application of a new bio-reactance device. J Card Fail 13:629–636CrossRefPubMed

32.

Reeves JT, Linehan JH, Stenmark KR (2005) Distensibility of the normal human lung circulation during exercise. Am J Physiol 288:L419–L425

33.

Butler J, Chomsky DB, Wilson JR (1999) Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 34:1802–1806CrossRefPubMed

34.

Tolle JJ, Waxman AB, Van Horn TL (2008) Exercise-induced pulmonary arterial hypertension. Circulation 118:2183–2189CrossRefPubMed

35.

Little WC, Kitzman DW, Cheng CP (2000) Diastolic dysfunction as a cause of exercise intolerance. Heart Fail Rev 5:301–306CrossRefPubMed

36.

Kitzman DW, Higginbotham MB, Cobb FR et al (1991) Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 17:1065–1072CrossRefPubMed

37.

Cheng CP, Noda T, Nozawa T (1993) Effect of heart failure on the mechanism of exercise-induced augmentation of mitral valve flow. Circ Res 72:795–806PubMed

38.

Skaluba SJ, Litwin SE (2004) Mechanisms of exercise intolerance: insights from tissue Doppler imaging. Circulation 109:972–977CrossRefPubMed

39.

Huez S, Naeije R (2007) Exercise stress tests for detection and evaluation of pulmonary hypertension. Eur Heart J 9:H17–H21CrossRef

40.

Galie N, Torbicki A, Barst R et al (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 25:2243–2278CrossRefPubMed

41.

Kovacs G, Berghold A, Scheidl S (2009) Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 34:888–894CrossRefPubMed

42.

Hoeper MM (2009) The new definition of pulmonary hypertension. Eur Respir J 34:790–791CrossRefPubMed

43.

Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT) et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34:1219–1263CrossRef

44.

Badesch DB, Champion HC, Sanchez MA (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54(1 Suppl):S55–S66CrossRefPubMed

45.

Nagaoka H, Isobe N, Kubota S et al (1997) Myocardial contractile reserve as prognostic determinant in patients with idiopathic dilated cardiomyopathy without overt heart failure. Chest 111:344–350CrossRefPubMed

46.

Plehn G, Vormbrock J, Perings C et al (2008) Loss of diastolic time as a mechanism of exercise-induced diastolic dysfunction in dilated cardiomyopathy. Am Heart J 155:1013–1018CrossRefPubMed

47.

Little WC (2005) Diastolic dysfunction beyond distensibility: adverse effects of ventricular dilatation. Circulation 112:2888–2890PubMed

48.

Packer M (1990) Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure. Circulation 81:78–86

49.

Brieke A, DeNofrio D (2005) Right ventricular dysfunction in chronic dilated cardiomyopathy and heart failure. Coron Artery Dis 16:5–1CrossRefPubMed

50.

Di Salvo TG, Mathier M, Semigran MJ et al (1998) Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 25:1143–1153

51.

Cheng CP, Igarashi Y, Little WC (1992) Mechanism of augmented rate of left ventricular filling during exercise. Circ Res 70:9–19PubMed

52.

Libonati JR (1999) Myocardial diastolic function and exercise. Med Sci Sports Exerc 31:1741–1747CrossRefPubMed

53.

Phan TT, Abozguia K, Nallur Shivu G et al (2009) Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise, associated with myocardial energy deficiency. J Am Coll Cardiol 54:402–409CrossRefPubMed

54.

Petrie MC, Hogg K, Caruana L et al (2004) Poor concordance of commonly used echocardiographic measures of left ventricular diastolic function in patients with suspected heart failure but preserved systolic function: is there a reliable echocardiographic measure of diastolic dysfunction? Heart 90:511–517CrossRefPubMed

55.

Kawaguchi M, Hay I, Fetics B et al (2003) Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 107:714–720CrossRefPubMed

56.

Maurer MS, Spevack D, Burkhoff D (2004) Diastolic dysfunction. Can it be diagnosed by Doppler echocardiography? J Am Coll Cardiol 44:1543–1549CrossRefPubMed

57.

Paulus WJ, Tschope C, Sanderson JE et al (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539–2550CrossRefPubMed

58.

Vasan RS, Levy D (2000) Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 101:2118–2121PubMed

59.

Najjar SS (2009) Heart failure with preserved ejection fraction failure to preserve, failure of reserve, and failure on the compliance curve. J Am Coll Cardiol 54:419–421CrossRefPubMed

60.

Marwick TH (2009) The deconvolution of diastole. J Am Coll Cardiol 54:47–48CrossRefPubMed

61.

Vahanian A, Baumgartner H, Bax J et al (2007) The task force on the management of valvular heart disease. ESC Guidelines on the management of valvular heart disease. Eur Heart J 28:230–268PubMed

62.

Pierard LA, Lancellotti P (2007) Stress testing in valve disease. Heart 93:766–772CrossRefPubMed

63.

Flachskampf FA, Fehske W, Reichenspurner H et al (2009) Kommentar zur Europäischen Leitlinie „Herzklappenerkrankungen“. Kardiologe 3:101–107CrossRef

64.

Tumminello G, Lancellotti P, Lempereur M et al (2007) Determinants of pulmonary artery hypertension at rest and during exercise in patients with heart failure. Eur Heart J 28:569–574CrossRefPubMed

65.

Kang SJ, Lim HS, Choi BJ et al (2008) The impact of exercise-induced changes in intraventricular dyssynchrony on functional improvement in patients with nonischemic cardiomyopathy. J Am Soc Echocardiogr 21:948–953CrossRefPubMed

66.

Bordachar P, Lafitte S, Reuter S et al (2006) Echocardiographic assessment during exercise of heart failure patients with cardiac resynchronization therapy. Am J Cardiol 97:1622–1625CrossRefPubMed

67.

Lafitte S, Bordachar P, Lafitte M et al (2006) Dynamic ventricular dyssynchrony: an exercise-echocardiography study. J Am Coll Cardiol 47:2253–2259CrossRefPubMed

68.

Kurita T, Onishi K, Dohi K et al (2007) Impact of heart rate on mechanical asynchrony and left ventricular contractility in patients with heart failure and normal QRS duration. Eur J Heart Fail 9:637–643CrossRefPubMed

69.

Chattopadhyay S, Alamgir MF, Nikitin NP et al (2008) The effect of pharmacological stress on intraventricular dyssynchrony in left ventricular systolic dysfunction. Eur J Heart Fail 10:412–420CrossRefPubMed

70.

Salukhe TV, Francis DP, Morgan M et al (2006) Mechanism of cardiac output gain from cardiac resynchronization therapy in patients with coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol 97:1358–1364CrossRefPubMed

71.

Duncan AM, Francis DP, Henein MY (2003) Limitation of cardiac output by total isovolumic time during pharmacologic stress in patients with dilated cardiomyopathy: activation-mediated effects of left bundle branch block and coronary artery disease. J Am Coll Cardiol 41:121–128CrossRefPubMed

72.

Plehn G, Vormbrock J, Machnick S et al (2008) Different effect of exercise on left ventricular diastolic time and interventricular dyssynchrony in heart failure patients with and without left bundle branch block. Int J Med Sci 5:333–340PubMed

73.

Coats CJ, Hollman A (2008) Hypertrophic cardiomyopathy: lessons from history. Heart 94:1258–1263CrossRefPubMed

74.

Plehn G, Vormbrock J, Meissner A, Trappe HJ (2009) Effect of exercise on the duration of diastole and on interventricular phase differences in patients with hypertrophic cardiomyopathy: relationship to cardiac output reserve. J Nucl Cardiol 16:233–243CrossRefPubMed

75.

Shah JS, Esteban MT, Thaman R et al (2008) Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 94:1288–1294CrossRefPubMed

76.

Murphy RT (2008) Bringing the obstruction back into hypertrophic cardiomyopathy. Heart 94:1249–1250CrossRefPubMed

77.

Lele SS, Thomson HL, Seo H et al (1995) Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics. Circulation 92:2886–2894PubMed

78.

Plehn G, Vormbrock J, Perings S (2010) Comparison of right ventricular functional response to exercise in hypertrophic versus idiopathic dilated cardiomyopathy. Am J Cardiol 105:116–121CrossRefPubMed

79.

Nagata M, Shimizu M, Ino H et al (2003) Hemodynamic changes and prognosis in patients with hypertrophic cardiomyopathy and abnormal blood pressure responses during exercise. Clin Cardiol 26:71–76CrossRefPubMed

80.

Cheng TO (2008) Exercise testing in hypertrophic cardiomyopathy. Int J Cardiol 123:219–220CrossRefPubMed

Titel: Stellenwert von Belastungsuntersuchungen bei nichtischämischen Herzerkrankungen
verfasst von: PD Dr. G. Plehn
T. Butz
A. Meissner
H. Yeni
M. Prull
J. Vormbrock
H.J. Trappe
Publikationsdatum: 01.08.2010
Verlag: Springer-Verlag
Erschienen in: Die Kardiologie / Ausgabe 4/2010
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI: https://doi.org/10.1007/s12181-010-0275-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Ryanodin-Rezeptor-Stabilisatoren

Kardiologische Betreuung in der Schwangerschaft

Kardiale Ionenkanalerkrankungen

34-jähriger Patient mit Linksschenkelblock und linksventrikulären Zysten

Immer weniger Myokardinfarkte bei amerikanischen Senioren